Clinical Trial Update: A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for a phase 1/2 study of a recombinant vaccinia virus (Pexa-Vec/JX-594) in malignant melanoma, sponsored by Jennerex Biotherapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pexa-Vec (JX-594) (recombinant vaccinia virus)

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED